Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Japanese MHLW grants reimbursement coverage for Cambridge MTWA test

The Japan's Ministry of Health, Labor and Welfare (MHLW) has granted reimbursement coverage for Cambridge Heart's microvolt t-wave alternans (MTWA) test.

Cambridge said the MTWA Test will be reimbursed for patients who are considered at risk for arrhythmias including patients with a history of heart attack, cardiomyopathy and Brugada syndrome.

Toho University Medical Center medicine professor Takanori Ikeda said a large body of clinical evidence supports the predictive value of the test which can now be used to help identify and manage the risk of arrhythmias.

Cambridge Heart president and CEO Ali Haghighi-Mood said the company markets its MTWA technology in Japan through its partnership with Fukuda Denshi.

"We look forward to working closely and strategically with our distribution partner in Japan to further expand that market and maximize the value of the relationship," Haghighi-Mood added.